Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 18:14:844.
doi: 10.1186/1471-2407-14-844.

Impact of preoperative anemia on relapse and survival in breast cancer patients

Affiliations

Impact of preoperative anemia on relapse and survival in breast cancer patients

YingJun Zhang et al. BMC Cancer. .

Abstract

Background: Previous studies have shown that preoperative anemia is correlated with the prognoses of various solid tumors. This study was performed to determine the effect of preoperative anemia on relapse and survival in patients with breast cancer.

Methods: A total of 2960 patients with breast cancer who underwent surgery between 2002 and 2008 at the Sun Yat-sen University Cancer Center (Guangzhou, PR China) were evaluated in a retrospective analysis. A total of 2123 qualified patients were divided into an anemic group [hemoglobin (Hb) < 12.0 g/dL, N = 535)] and a nonanemic group (Hb ≥ 12.0 g/dL, N = 1588). The effects of anemia on local relapse-free survival (LRFS), lymph node metastasis-free survival (LNMFS), distant metastasis-free survival (DMFS), relapse-free survival (RFS), and overall survival (OS) were assessed using Kaplan-Meier analysis. Independent prognostic factors were identified in the final multivariate Cox proportional hazards regression model.

Results: Among the 2123 women who qualified for the analysis, 535 (25.2%) had a Hb level < 12.0 g/dL. The Kaplan-Meier curves showed that anemic patients had worse LRFS, LNMFS, DMFS, RFS, and OS than nonanemic patients, even in the same clinical stage of breast cancer. Cox proportional hazards regression model indicated that preoperative anemia was an independent prognostic factor of LRFS, LNMFS, DMFS, RFS, and OS for patients with breast cancer.

Conclusions: Preoperative anemia was independently associated with poor prognosis of patients with breast cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the patient grouping.
Figure 2
Figure 2
LRFS, LNMFS, DMFS, RFS, and OS of patients with and without anemia. A. LRFS for patients with Hb ≥ 12 g/dL versus Hb < 12 g/dL. B. LNMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL. C. DMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL. D. RFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL. E. OS for patients with Hb ≥12 g/dL versus Hb <12 g/dL.
Figure 3
Figure 3
LRFS, LNMFS, DMFS, RFS, and OS of patients in stage I with and without anemia. A. LRFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage I. B. LNMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage I. C. DMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage I. D. RFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage I. E. OS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage I.
Figure 4
Figure 4
LRFS, LNMFS, DMFS, RFS, and OS for patients in stage II with and without anemia. A. LRFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage II. B. LNMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage II. C. DMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage II. D. RFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage II. E. OS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage II.
Figure 5
Figure 5
LRFS, LNMFS, DMFS, RFS, and OS for patients in stage III with and without anemia. A. LRFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage III. B. LNMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage III. C. DMFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage III. D. RFS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage III. E. OS for patients with Hb ≥12 g/dL versus Hb <12 g/dL in stage III.
Figure 6
Figure 6
LRFS, LNMFS, DMFS, RFS, and OS for patients without anemia versus mild anemia. A. LRFS for patients with Hb ≥12 g/dL versus 9 < Hb <12 g/dL. B. LNMFS for patients with Hb ≥12 g/dL versus 9 < Hb <12 g/dL. C. DMFS for patients with Hb ≥12 g/dL versus 9 < Hb <12 g/dL. D. RFS for patients with Hb ≥12 g/dL versus 9 < Hb <12 g/dL. E. OS for patients with Hb ≥12 g/dL versus 9 < Hb <12 g/dL.

References

    1. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):11S–26S. doi: 10.1016/j.amjmed.2003.12.008. - DOI - PubMed
    1. Hu K, Harrison LB. Impact of anemia in patients with head and neck cancer treated with radiation therapy. Curr Treat Options Oncol. 2005;6(1):31–45. doi: 10.1007/s11864-005-0011-4. - DOI - PubMed
    1. Choi YS, Yi CM, Sin JI, Ye GW, Shin IH, Lee TS. Impact of hemoglobin on survival of cervical carcinoma patients treated with concurrent chemoradiotherapy is dependent on lymph node metastasis findings by magnetic resonance imaging. Int J Gynecol Cancer. 2006;16(5):1846–1854. doi: 10.1111/j.1525-1438.2006.00666.x. - DOI - PubMed
    1. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86(8):1528–1536. doi: 10.1002/(SICI)1097-0142(19991015)86:8<1528::AID-CNCR20>3.0.CO;2-E. - DOI - PubMed
    1. Dunphy EP, Petersen IA, Cox RS, Bagshaw MA. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1989;16(5):1173–1178. doi: 10.1016/0360-3016(89)90277-0. - DOI - PubMed
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/844/prepub

Publication types